Abstract 24P
Background
Non-invasive early diagnosis of cancer is a highly desirable goal in oncology. Plasma proteins have potential application in clinical practice as cancer biomarker. However, their profiling in presence of small tumors, entails technical and biological challenges. Cutting-edge technologies could overcome these limitations. In the present study, we describe preliminary data on the assessment of circulating proteins in early breast cancer (eBC) patients from the RENOVATE trial by employing two high-throughput proteomics approaches.
Methods
The RENOVATE trial (NCT04781062) enrolled women with suspect breast lesions ≤ 2 cm. They were asked to donate blood sample (detailed information in Ravera et al., BMJ, 2021). Plasma samples from 31 cancer, 29 benign and 20 healthy donors, matched by age, body mass index (BMI), menopausal and smoking status, were tested by aptamer-based proteomics arrays (SomaScan Somalogic®). Nearly 370 proteins were reassessed on the same biospecimens, leveraging an antibody-DNA linker technology assay (Oncology panel, Olink®). Variance analysis was performed using ANOVA. Statistical tests with a p-value < 0.01 were considered significant. Proteomics signatures were identified by a penalized linear model (glmnet R package). The two assays correlation was evaluated using Intra-class correlation (ICC).
Results
Out of 7596 proteins, 29 showed a significant differences across the 3 groups. The detected proteins are mainly involved in differentiation, migration, and cell death pathways. The two platforms shared 300 targets; 99% (n=296) passed the quality control step. The two used methodologies displayed moderately consistent results with 22% of probes (n=66) with an ICC index ≥ 0.5.
Conclusions
In the present study, we performed a broad analysis of human circulating proteins. We detected proteins associated with early BC related to pathways influencing cancer development. Data were validated by an orthogonal technology. Despite the potentiality in early diagnosis, the application of advanced methodologies is constrained by costs, and the majority of detected biomarkers have not yet been validated by standardized routine assays. We are currently working on the validation of our findings by implementing low-throughput and low-cost methods.
Editorial acknowledgement
Clinical trial identification
NCT04781062 study start: 2021-01-19.
Legal entity responsible for the study
IRCCS Ospedale Policlinico San Martino.
Funding
AIRC - Italian Foundation for Cancer Research.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
52P - The concentration of mutated copies of driver genes in plasma closely mirrors the disease course in colorectal cancer, lung cancer, and melanoma patients
Presenter: Ekaterina Kuligina
Session: Cocktail & Poster Display session
Resources:
Abstract
53P - Heterogeneous characteristics of KRAS mutation subtypes in surgically resected lung adenocarcinomas
Presenter: Kazuya Takamochi
Session: Cocktail & Poster Display session
Resources:
Abstract
54P - ATRX-deficient IDH-wildtype adult high-grade gliomas display novel, clinically relevant genetic patterns by comprehensive genomic profiling
Presenter: Gábor Bedics
Session: Cocktail & Poster Display session
Resources:
Abstract
55P - EGFR variant allele frequency (VAF) impacts on metastatic NSCLC patients outcome during first-line osimertinib
Presenter: Silvia Teresa Riva
Session: Cocktail & Poster Display session
Resources:
Abstract
57P - Clinical characteristics and outcomes in non-small cell lung cancer (NSCLC) with tumour and germline BRCA1/2 mutations
Presenter: Greydon Arthur
Session: Cocktail & Poster Display session
Resources:
Abstract
58P - Molecular investigation using microarray-based comparative genomic hybridization in patients with myelodysplastic syndrome and normal karyotype
Presenter: Mohamed abd naceur AMMAR
Session: Cocktail & Poster Display session
Resources:
Abstract
59P - Unraveling methylation signatures in RAS/BRAF wild-type colorectal cancer patients to identify predictive biomarkers for anti-epidermal growth factor receptor therapy
Presenter: Ana Regina de Abreu
Session: Cocktail & Poster Display session
Resources:
Abstract
60P - Spindle cell sarcomas with tyrosine kinase rearrangement
Presenter: Lenka Krsková
Session: Cocktail & Poster Display session
Resources:
Abstract
61P - Deconvoluting the intra-tumour heterogeneity and subclonal evolution of CDK4/6 inhibitor resistance in ER+ breast cancer
Presenter: Ioanna Mavrommatis
Session: Cocktail & Poster Display session
Resources:
Abstract
62P - Role of IL6 (C-174G) polymorphism in the development of cervical intraepithelial neoplasia
Presenter: Tatyana Abakumova
Session: Cocktail & Poster Display session
Resources:
Abstract